Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Supplement AER guidance questioned

This article was originally published in The Tan Sheet

Executive Summary

FDA should define more clearly elements of its serious adverse event report guidance for dietary supplements, a food and drug attorney says. A. Wes Siegner, of Hyman, Phelps & McNamara in Washington, tells FDA his client Nutraceutical Corp. is concerned about the agency's recommendation that a person responsible for submitting AERs use "diligent efforts" to obtain data from a patient or reporter. Siegner's Nov. 23 1letter says, "If FDA intends to equate 'diligent efforts' with the use of health care practitioners or other methods to elicit the minimum data elements, FDA should" state its expectations. Siegner also takes issue with the agency's definitions of "identifiable patient," "initial reporter" and "serious" AERs in the June 2009 2guidance (3"The Tan Sheet" July 20, 2009)

You may also be interested in...

Final Guidance For Reporting Adverse Events Gets Serious On Definitions

A report of emergency room treatment connected to use of a dietary supplement may not connote a serious adverse event, FDA says in the final guidance on the reporting and recordkeeping of AE information for supplements

Prenatal Vitamin D Benefit In Preventing Childhood Asthma Fades By Age 6

University of Rochester researchers say a benefit of daily prenatal vitamin D in preventing asthma in children up to 3 found in their 2016 study doesn't extend until age 6. They encourage more research, including analyzing whether supplementation should continue in young children.

UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System

At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts